Strafford will be offering a webinar entitled "Patent Exclusivity Health Checks for Small Molecules: Are Your U.S. Patents Ready to Maximize ROI? -- Phase II Efficacy Trials, Phase III Clinical Trials, NDA Submission, Approval and Marketing" on March 8, 2018 from 1:00 to 2:30 pm (EST). Thomas L. Irving, Shana K. Cyr, Mark J. Feldstein, and John D. Livingstone of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on the essentials of patent exclusivity that are in critical need of independent checking, and discuss crucial health checks on U.S. patent exclusivity for small molecules in Phase II efficacy trials and proceeding through large-scale randomized Phase III clinical trials, submission of the NDA, and subsequent approval and marketing. The webinar will review the following issues:
• What can be done if sub-optimal protection or even serious defects are discovered during the "health check"?
• Are Orange Book listed patent claims definite or enabled under the current standards?
• Is there a need for supplemental examination to clear the path to enforceability?
The registration fee for the webcast is $297. Those interested in registering for the webinar, can do so here.
Comments